The moderate-to-high in vitro cytotoxicity against ovarian A2780 (IC50 = 4.7-14.4 μM), prostate LNCaP (IC50 = 18.7-30.8 μM) and prostate PC-3 (IC50 = 17.6-42.3 μM) human cancer cell lines of the platinum(II) cyclobutane-1,1'-dicarboxylato complexes [Pt(cbdc)(naza)2] (1-6; cbdc = cyclobutane-1,1'-dicarboxylate(2-); naza = halogeno-substituted 7-azaindoles), derived from the anticancer metallodrug carboplatin, are reported. The complexes containing the chloro- and bromo-substituted 7-azaindoles (1, 2, and 4-6) showed a significantly higher (p < 0.05) cytotoxicity against A2780 cell line as compared to cisplatin used as a reference drug. Addition of the non-toxic concentration (5.0 μM) of L-buthionine sulfoximine (L-BSO, an effective inhibitor of γ-glutamylcysteine synthase) markedly increases the in vitro cytotoxicity of the selected complex 3 against A2780 cancer cell line by a factor of about 4.4. The cytotoxicity against A2780 and LNCaP cells, as well as the DNA platination, were effectively enhanced by UVA light irradiation (λmax = 365 nm) of the complexes, with the highest phototoxicity determined for compound 3, resulting in a 4-fold decline in the A2780 cells viability from 25.1% to 6.1%. The 1H NMR and ESI-MS experiments suggested that the complexes did not interact with glutathione as well as their ability to interact with guanosine monophosphate. The studies also confirmed UVA light induced the formation of the cis [Pt(H2O)2(cbdc`)(naza)] intermediate, where cbdc` represents monodentate-coordinated cbdc ligand, which is thought to be responsible for the enhanced cytotoxicity. This is further supported by the results of transcription mapping experiments showing that the studied complexes preferentially form the bifunctional adducts with DNA under UVA irradiation, in contrast to the formation of the less effective monofunctional adducts in dark.

Centre of the Region Haná for Biotechnological and Agricultural Research and Department of Biophysics Faculty of Science Palacký University Olomouc Czech Republic

Department of Biophysics Faculty of Science Palacký University Olomouc Czech Republic

Regional Centre of Advanced Technologies and Materials and Department of Cell Biology and Genetics Faculty of Science Palacký University Olomouc Czech Republic

Regional Centre of Advanced Technologies and Materials and Department of Inorganic Chemistry Faculty of Science Palacký University Olomouc Czech Republic

Zobrazit více v PubMed

Rosenberg B, VanCamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965; 205: 698–699. PubMed

Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature Rev Cancer. 2007; 7: 573–584. PubMed

Barry NPE, Sadler PJ. Exploration of the medical periodic table: towards new targets. Chem Commun. 2013; 49: 5106–5131. 10.1039/c3cc41143e PubMed DOI

Kelland LR, Farrell NP. Platinum-Based Drugs in Cancer Therapy. Humana: Totowa; 2000.

Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22: 7265–7279. PubMed

Smith NA, Sadler PJ. Photoactivatable metal complexes: from theory to applications in biotechnology and medicine. Phil Trans R Soc. 2013; A 371: 20120519 10.1098/rsta.2012.0519 PubMed DOI PMC

Mackay FS, Woods JA, Heringova P, Kasparkova J, Pizarro AM, Moggach SA, et al. A potent cytotoxic photoactivated platinum complex. Proc Natl Acad Sci USA. 2007; 104: 20743–20748. PubMed PMC

Mlcouskova J, Stepankova J, Brabec V. Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding. J Biol Inorg Chem. 2012; 17: 891–898. 10.1007/s00775-012-0906-z PubMed DOI

Zhao J, Gou S, Sun Y, Fang L, Wang Z. Antitumor platinum(II) complexes containing platinum-based moieties of present platinum drugs and furoxan groups as nitric oxide donors: synthesis, DNA interaction, and cytotoxicity. Inorg Chem. 2012; 51: 10317–10324. PubMed

Dvořák L, Popa I, Štarha P, Trávníček Z. In vitro cytotoxic-active platinum(II) complexes derived from carboplatin and involving purine derivatives. Eur J Inorg Chem. 2010; 3441–3448.

Štarha P, Trávníček Z, Popa A, Popa I, Muchová T, Brabec V. How to modify 7-azaindole to form cytotoxic Pt(II) complexes: highly in vitro anticancer effective cisplatin derivatives involving halogeno-substituted 7-azaindole. J Inorg Biochem. 2012; 115: 57–63. 10.1016/j.jinorgbio.2012.05.006 PubMed DOI

Muchová T, Prachařová J, Štarha P, Olivová R, Vrána O, Benesova B, et al. Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells. J Biol Inorg Chem. 2013; 18: 579–589. 10.1007/s00775-013-1003-7 PubMed DOI

Štarha P, Hošek J, Vančo J, Dvořák Z, Suchý P, Popa I, et al. Pharmacological and molecular effects of platinum(II) complexes involving 7-azaindole derivatives. PLoS ONE. 2014; 9: e90341 10.1371/journal.pone.0090341 PubMed DOI PMC

New EJ, Roche C, Madawala R, Zhang JZ, Hambley TW. Fluorescent analogues of quinoline reveal amine ligand loss from cis and trans platinum(II) complexes in cancer cells. J Inorg Biochem. 2009; 103: 1120–1125. 10.1016/j.jinorgbio.2009.05.005 PubMed DOI

Zamora A, Rodríguez V, Cutillas N, Yellol GS, Espinosa A, Samper KG, et al. New steroidal 7-azaindole platinum(II) antitumor complexes. J Inorg Biochem. 2013; 128: 48–56. 10.1016/j.jinorgbio.2013.07.010 PubMed DOI

Brabec V, Paleček E. Interaction of nucleic acids with electrically charged surfaces: II. Conformational changes in double-helical polynucleotides. Biophys Chem. 1976; 4: 79–92. PubMed

Dhara SC. A rapid method for the synthesis of cis-[Pt(NH3)2Cl2]. Indian J Chem. 1970; 8: 193–194.

Romero-Canelón I, Sadler PJ. Next-generation metal anticancer complexes: multitargeting via redox modulation. Inorg Chem. 2013; 52: 12276–12291. 10.1021/ic400835n PubMed DOI

Brabec V, Leng M. DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc Natl Acad Sci USA. 1993; 90: 5345–5349. PubMed PMC

Farrell N, Qu Y, Feng L, Van Houten B. Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. Biochemistry. 1990; 29: 9522–9531. PubMed

Butour JL, Macquet JP. Differentiation of DNA—platinum complexes by fluorescence. The use of an intercalating dye as a probe. Eur J Biochem. 1977; 78: 455–463. PubMed

Butour JL, Alvinerie P, Souchard JP, Colson P, Houssier C, Johnson NP. Effect of the amine nonleaving group on the structure and stability of DNA complexes with cis-[Pt(R-NH2)2(NO3)2]. Eur J Biochem. 1991; 202: 975–980. PubMed

Fichtinger-Schepman AMJ, Van der Veer JL, Den Hartog JHJ, Lohman PHM, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 1985; 24: 707–713. PubMed

Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharm Ther. 1987; 34: 155–166. PubMed

Ramos-Lima FJ, Vrana O, Quiroga AG, Navarro-Ranninger C, Halamikova A, Rybnickova H, et al. Structural characterization, DNA interactions, and cytotoxicity of new transplatin analogues containing one aliphatic and one planar heterocyclic amine ligand. J Med Chem. 2006; 49: 2640–2651. PubMed

Štarha P, Marek J, Trávníček Z. Cisplatin and oxaliplatin derivatives involving 7-azaindole: Structural characterisations. Polyhedron. 2012; 33: 404–409.

Zhao Y, Woods JA, Farrer NJ, Robinson KS, Pracharova J, Kasparkova J, et al. Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts. Chem-Eur J. 2013; 19: 9578–9591. 10.1002/chem.201300374 PubMed DOI PMC

Jansen BAJ, Brouwer J, Reedijk J. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J Inorg Biochem. 2002; 89: 197–202. PubMed

Romero-Canelón I, Salassa L, Sadler PJ. The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway. J Med Chem. 2013; 56: 1291–1300. 10.1021/jm3017442 PubMed DOI

Frey U, Ranford JD, Sadler PJ. Ring-opening reactions of the anticancer drug carboplatin: NMR characterization of cis-[Pt(NH3)2(CBDCA-O)(5'-GMP-N7)] in solution. Inorg Chem. 1993; 32: 1333–1340.

Hay RW, Miller S. Reactions of platinum(ll) anticancer drugs. Kinetics of acid hydrolysis of cis-diammine(cyclobutane-l,1-dicarboxylato)platinum(II) "Carboplatin". Polyhedron. 1998; 17: 2337–2343.

Pavelka M, Fatima M, Lucas A, Russo N. On the hydrolysis mechanism of the second-generation anticancer drug Carboplatin. Chem-Eur J. 2007; 13: 10108–10116. PubMed

Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 1999; 99: 2467–2498. PubMed

Brabec V. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol. 2002; 71: 1–68. PubMed

Lemaire MA, Schwartz A, Rahmouni AR, Leng M. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc Natl Acad Sci USA. 1991; 88: 1982–1985. PubMed PMC

Brabec V, Boudny V, Balcarova Z. Monofunctional adducts of platinum(II) produce in DNA a sequence-dependent local denaturation. Biochemistry. 1994; 33: 1316–1322. PubMed

In vitro anticancer active cis-Pt(II)-diiodido complexes containing 4-azaindoles

Platinum(II) Iodido Complexes of 7-Azaindoles with Significant Antiproliferative Effects: An Old Story Revisited with Unexpected Outcomes

Organometallic Half-Sandwich Dichloridoruthenium(II) Complexes with 7-Azaindoles: Synthesis, Characterization and Elucidation of Their Anticancer Inactivity against A2780 Cell Line